Screening of antimalarial drugs: An overview

Kalra, Bhupinder Singh; Chawla, S.; Gupta, P.; Valecha, N.
February 2006
Indian Journal of Pharmacology;Feb2006, Vol. 38 Issue 1, p5
Academic Journal
Efforts to discover and develop new antimalarial drugs have increased dramatically in recent years mainly because of resistance to existing antimalarial drugs. Selection of candidate drugs for clinical trials in man and the design of clinical protocols are based upon consideration of data from a battery of preclinical test systems. All compounds are assessed initially in one or more primary screening models. A compound which is considered 'active' by well established criteria in primary screening test is considered for further evaluation in successively more clinical tests. At the end of each stage of testing, a decision is taken to advance the compound to the next stage or discontinue it. Primary screening tests should have optimal sensitivity, a high degree of reproducibility, high throughput, requiring a minimum quantity of test compound and should bear low cost. As there is growing need for newer and more efficacious antimalarial drugs especially in tropical countries, more sensitive and economical screening models are needed. This review is an update of various conventional and latest in vitro and in vivo screening methods being used for evaluation of antimalarial compounds.


Related Articles

  • Antimalarial drug discovery: efficacy models for compound screening. Fidock, David A.; Rosenthal, Philip I.; Croft, Simon L.; Brun, Reto; Nwaka, Solomon // Nature Reviews Drug Discovery;Jun2004, Vol. 3 Issue 6, p509 

    Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to develop safe and affordable new drugs to counter the spread of malaria parasites that are resistant to existing agents. Drug efficacy, pharmacology and toxicity are important parameters in the selection of...

  • Antimalarials: Joint attack on malaria. Ellis, Clare // Nature Reviews Drug Discovery;Sep2004, Vol. 3 Issue 9, p735 

    Reports that a multidisciplinary team of scientists have developed an antimalarial drug candidate that will move into human clinical trials in late 2004. Publication of the researchers' work in the journal "Nature"; Overview of the disease; Selection of the drug candidate.

  • Computational studies of new potential antimalarial compounds – Stereoelectronic complementarity with the receptor. Portela, César; Afonso, Carlos M. M.; Pinto, Madalena M. M.; João Ramos, Maria // Journal of Computer-Aided Molecular Design;Sep2003, Vol. 17 Issue 9, p583 

    One of the most important pharmacological mechanisms of antimalarial action is the inhibition of the aggregation of hematin into hemozoin. We present a group of new potential antimalarial molecules for which we have performed a DFT study of their stereoelectronic properties. Additionally, the...

  • Identification of an antimalarial synthetic trioxolane drug development candidate. Vennerstrom, Jonathan L.; Arbe-Barnes, Sarah; Brun, Reto; Charman, Susan A.; Chiu, Francis C. K.; Chollet, Jacques; Dong, Yuxiang; Dorn, Arnulf; Hunziker, Daniel; Matile, Hugues; McIntosh, Kylie; Padmanilayam, Maniyan; Tomas, Josefina Santo; Scheurer, Christian; Scorneaux, Bernard; Tang, Yuanqing; Urwyler, Heinrich; Wittlin, Sergio; Charman, William N. // Nature;8/19/2004, Vol. 430 Issue 7002, p900 

    The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs...

  • Monitoring Antimalarial Drug Efficacy. Ringwald, P. // Clinical Infectious Diseases;4/15/2004, Vol. 38 Issue 8, p1192 

    Presents letters to the editor on antimalarial drug efficacy, published in the April 15, 2004 issue of the journal "Clnical Infectious Diseases." Effects of the chemical compound sulfadoxine-pyrimethamine therapy; Results of clinical trials for drug resistance; Antimalarial drug efficacy in low...

  • Synthesis and Antimalarial Activity of 1,2,4,5-Tetraoxanes. Yuxiang Dong, J.D. // Mini Reviews in Medicinal Chemistry;Apr2002, Vol. 2 Issue 2, p113 

    Methods for formation of 1,2,4,5-tetraoxanes are summarized and antimalarial activities of 1,2,4,5-tetraoxanes are discussed.

  • Clioquinol -- A Novel Copper-Dependent and Independent Proteasome Inhibitor. Schimmer, A. D. // Current Cancer Drug Targets;Mar2011, Vol. 11 Issue 3, p325 

    No abstract available.

  • Protein-Drug Interaction Studies for Development of Drugs Against Plasmodium falciparum. De Azevedo Jr., Walter Filgueira; Caceres, Rafael Andrade; Pauli, Ivani; S. M. Timmers, Luís Fernando; Barcellos, Guy Barros; Rocha, Kelen Beiestorf; Pereira Soares, Milena Botelho // Current Drug Targets;Mar2009, Vol. 10 Issue 3, p271 

    The study of protein-drug interaction is of pivotal importance to understand the structural features essential for ligand affinity. The explosion of information about protein structures has paved the way to develop structure-based virtual screening approaches. Parasitic protein kinases have been...

  • Phylogenetic Analysis and Protein Modeling of Plasmodium falciparum Aspartate Transcarbamoylase (ATCase). Depamede, S. N.; Menz, I. // Research Journal of Microbiology;2011, Vol. 6 Issue 7, p599 

    Unlike most mammalian cells, Plasmodium sp., are unable to utilize preformed pyrimidine bases and nucleosides hence they are reliant solely on de novo pathway. Aspartate transcarbamoylase (ATCase, EG catalyzes the first committed step in de novo pyrimidine biosynthesis pathway, is a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics